Trial Profile
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Goserelin; Leuprorelin
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms COMPLEEMENT-1
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 30 Dec 2022 This trial has been completed in Czech Republic according to European Clinical Trials Database record.
- 29 Dec 2022 Status changed from active, no longer recruiting to completed.
- 01 Nov 2022 This trial has been completed in Bulgaria according to European Clinical Trials Database record.